BRCA2 and ovarian carcinoma: Retention of the normal BRCA1 or BRCA2 allele is observed in 7% and 16% of BRCA1 and BRCA2 germline mutation-associated ovarian cancers, and it is associated with decreased overall survival in patients treated with platinum chemotherapy [99].